Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - mupirocin 20 mg/g;   - topical ointment - 2% w/w - active: mupirocin 20 mg/g   excipient: macrogol 3350 macrogol 400 - mupider ointment is indicated for the topical treatment of the following primary and secondary skin infections due to susceptible pathogens: primary pyodermas such as impetigo, folliculitis, furunculosis, ecthyma; secondary infected dermatoses such as eczema, psoriasis, atopic dermatitis, herpes, epidermolysis bullosa, icthyosis, and infected traumatic lesions such as ulcers, minor burns, cuts, abrasions, lacerations, wounds, biopsy sites, surgical incisions and insect bites. prophylactically, mupider ointment may be used to prevent bacterial contamination in minor burns, biopsy sites, incisions and other clean lesions. for abrasions, minor cuts and wounds the prophylatic use of mupider may prevent the development of infection and permit wound healing.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - nortriptyline hydrochloride 11.4mg equivalent to nortriptyline base 10 mg - tablet - 10 mg - active: nortriptyline hydrochloride 11.4mg equivalent to nortriptyline base 10 mg excipient: lactose monohydrate magnesium stearate maize starch - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - nortriptyline hydrochloride 28.5mg equivalent to nortriptyline base 25 mg - tablet - 25 mg - active: nortriptyline hydrochloride 28.5mg equivalent to nortriptyline base 25 mg excipient: lactose monohydrate magnesium stearate maize starch - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 10mg;   - modified release tablet - 10 mg - active: oxycodone hydrochloride 10mg   excipient: colloidal silicon dioxide ethylcellulose ferrous oxide hyprolose hypromellose     iron oxide red macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 powdered cellulose propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 20mg;   - modified release tablet - 20 mg - active: oxycodone hydrochloride 20mg   excipient: colloidal silicon dioxide ethylcellulose hyprolose hypromellose     iron oxide red macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 40mg;   - modified release tablet - 40 mg - active: oxycodone hydrochloride 40mg   excipient: colloidal silicon dioxide ethylcellulose hyprolose hypromellose     iron oxide red iron oxide yellow macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxycodone hydrochloride 80mg;   - modified release tablet - 80 mg - active: oxycodone hydrochloride 80mg   excipient: colloidal silicon dioxide ethylcellulose hyprolose hypromellose     iron oxide yellow macrogol 6000   magnesium stearate microcrystalline cellulose opacode black s-1-17860 propylene glycol purified talc   sugar spheres titanium dioxide - management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxytocin 10 iu/ml equivalent to 16.6 mcg/ml;   - solution for injection - 10 iu/ml - active: oxytocin 10 iu/ml equivalent to 16.6 mcg/ml   excipient: glacial acetic acid sodium acetate sodium chloride water for injection - antepartum: · induction of labour for medical reasons, e.g. in cases of post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia). · enhancement of labour in selected cases of uterine inertia. · oxytocin injection bp may also be indicated in early stage of pregnancy, as adjunctive therapy for management of incomplete, inevitable or missed abortion. postpartum: · during caesarean section, after the delivery of the child. · prevention and treatment of postpartum uterine atony and haemorrhage.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxytocin 5 iu/ml equivalent to 8.3 mcg/ml;   - solution for injection - 5 iu/ml - active: oxytocin 5 iu/ml equivalent to 8.3 mcg/ml   excipient: glacial acetic acid sodium acetate sodium chloride water for injection - antepartum: · induction of labour for medical reasons, e.g. in cases of post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia). · enhancement of labour in selected cases of uterine inertia. · oxytocin injection bp may also be indicated in early stage of pregnancy, as adjunctive therapy for management of incomplete, inevitable or missed abortion. postpartum: · during caesarean section, after the delivery of the child. · prevention and treatment of postpartum uterine atony and haemorrhage.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - piperacillin monohydrate 4000mg; tazobactam 500mg;   - powder for injection - 4g/0.5g - active: piperacillin monohydrate 4000mg tazobactam 500mg   excipient: glacial acetic acid sodium bicarbonate - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piptaz bnm plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piptaz bnm is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz bnm is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.